Leerink Partnrs Raises Earnings Estimates for REGENXBIO

REGENXBIO Inc. (NASDAQ:RGNX) – Equities researchers at Leerink Partnrs increased their FY2026 earnings estimates for REGENXBIO in a research report issued to clients and investors on Wednesday, January 29th. Leerink Partnrs analyst M. Foroohar now forecasts that the biotechnology company will post earnings of $0.28 per share for the year, up from their prior forecast of ($0.52). The consensus estimate for REGENXBIO’s current full-year earnings is ($4.85) per share. Leerink Partnrs also issued estimates for REGENXBIO’s FY2027 earnings at ($0.14) EPS, FY2028 earnings at $0.59 EPS and FY2029 earnings at $1.21 EPS.

Several other brokerages have also issued reports on RGNX. Royal Bank of Canada restated an “outperform” rating and set a $30.00 target price on shares of REGENXBIO in a research report on Tuesday, January 21st. Chardan Capital restated a “buy” rating and set a $52.00 target price on shares of REGENXBIO in a research report on Wednesday, November 20th. StockNews.com lowered shares of REGENXBIO from a “hold” rating to a “sell” rating in a research report on Thursday, January 23rd. Raymond James restated an “outperform” rating and set a $18.00 target price on shares of REGENXBIO in a research report on Thursday, October 10th. Finally, Morgan Stanley restated an “overweight” rating and set a $22.00 target price on shares of REGENXBIO in a research report on Friday, November 15th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $34.82.

REGENXBIO Trading Up 7.8 %

Shares of NASDAQ RGNX opened at $8.43 on Monday. The firm has a 50 day moving average of $8.18 and a 200 day moving average of $10.13. The firm has a market capitalization of $417.62 million, a price-to-earnings ratio of -1.68 and a beta of 1.29. REGENXBIO has a 12-month low of $6.56 and a 12-month high of $28.80.

Hedge Funds Weigh In On REGENXBIO

Several hedge funds have recently modified their holdings of the stock. Y Intercept Hong Kong Ltd purchased a new position in shares of REGENXBIO in the fourth quarter worth $1,062,000. Hennion & Walsh Asset Management Inc. raised its stake in REGENXBIO by 8.6% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 164,729 shares of the biotechnology company’s stock valued at $1,273,000 after purchasing an additional 13,014 shares in the last quarter. Assenagon Asset Management S.A. raised its stake in REGENXBIO by 53.0% during the fourth quarter. Assenagon Asset Management S.A. now owns 856,572 shares of the biotechnology company’s stock valued at $6,621,000 after purchasing an additional 296,700 shares in the last quarter. GAMMA Investing LLC raised its stake in REGENXBIO by 273.1% during the fourth quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 2,510 shares in the last quarter. Finally, Barclays PLC raised its stake in REGENXBIO by 141.3% during the third quarter. Barclays PLC now owns 116,024 shares of the biotechnology company’s stock valued at $1,217,000 after purchasing an additional 67,948 shares in the last quarter. Hedge funds and other institutional investors own 88.08% of the company’s stock.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.